What is Antiverse?
Antiverse is a pioneering tech-bio enterprise specializing in the development of next-generation computational antibody design technology. By integrating artificial intelligence with structural biology, the company enables the design of therapeutics for historically challenging drug targets. This market position allows Antiverse to bridge the gap between complex biological requirements and scalable drug discovery, providing a critical service to the pharmaceutical industry. The company's focus on G-protein coupled receptors and ion channels places it at the forefront of precision medicine, where traditional discovery methods often face significant limitations.
How much funding has Antiverse raised?
Antiverse has raised a total of $18.9M across 4 funding rounds:
Angel/Seed
$2M
Other Financing Round
$3M
Angel/Seed
$4.6M
Series A
$9.3M
Angel/Seed (2021): $2M with participation from Development Bank of Wales, Tensor Ventures, Ed Parkinson, Syndicate Room, The Cambridge Angels, Angel Co-Investment Fund, and wren capital
Other Financing Round (2023): $3M led by Deep Science Ventures, Innospark Ventures, AngelHub, and Tensor Ventures
Angel/Seed (2024): $4.6M supported by i&i Biotech Fund, Kadmos Capital, Tensor Ventures, AngelHub, and Innospark Ventures
Series A (2026): $9.3M featuring Soulmates Ventures, Development Bank of Wales, Innovative Investments Capital Funding Group, and Kadmos Capital
Key Investors in Antiverse
Soulmates Ventures
A sustainable venture capital fund that accelerates innovative entrepreneurs focused on creating profitable solutions for a sustainable future across various sectors including healthcare.
Development Bank of Wales
A financial institution backed by the Welsh Government that provides sustainable business finance and equity support for technology ventures.
Kadmos Capital
An investment firm focused on addressing humanity's most pressing problems by supporting innovative solutions that contribute to positive global change.
What's next for Antiverse?
With the recent influx of $9.3M, Antiverse is poised to transition from its foundational research phase into a period of aggressive commercial scaling and clinical validation. The strategic roadmap likely involves expanding its computational infrastructure and deepening partnerships with global pharmaceutical entities to validate its design platform in real-world drug development pipelines. As the company continues to refine its AI-driven discovery engine, it will likely focus on securing additional intellectual property and expanding its therapeutic portfolio. The ongoing support from specialized venture capital firms suggests a long-term commitment to establishing Antiverse as a standard-bearer in the computational biology sector, with a clear path toward transforming the efficiency of antibody-based therapeutic discovery.
See full Antiverse company page
